Interactions between the intrinsically disordered proteins β‐Synuclein and α‐Synuclein
Several intrinsically disordered proteins have been implicated in the process of amyloid fibril
formation in neurodegenerative disease, and developing approaches to inhibit the …
formation in neurodegenerative disease, and developing approaches to inhibit the …
Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies
Objective Understanding the heterogeneous pathology in Alzheimer's disease and related
tauopathies is one of the most urgent and fundamental challenges facing the discovery of …
tauopathies is one of the most urgent and fundamental challenges facing the discovery of …
Critical nucleus of Greek-key-like core of α-synuclein protofibril and its disruption by dopamine and norepinephrine
The formation of amyloid fibrils by α-synuclein (αS) protein inside the Lewy bodies and Lewy
neurites is the prominent pathological hallmark of Parkinson's disease (PD). The fibrillation …
neurites is the prominent pathological hallmark of Parkinson's disease (PD). The fibrillation …
Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors
We have developed a high-throughput drug discovery platform, measuring fluorescence
resonance energy transfer (FRET) with fluorescent alpha-synuclein (αSN) biosensors, to …
resonance energy transfer (FRET) with fluorescent alpha-synuclein (αSN) biosensors, to …
[HTML][HTML] Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity
The aggregation of α-synuclein (α-syn) into amyloid fibrils is a major pathological hallmark of
Parkinson's disease (PD) and other synucleinopathies. The mechanisms underlying the …
Parkinson's disease (PD) and other synucleinopathies. The mechanisms underlying the …
CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
Parkinson's disease (PD) is a neurodegenerative disorder for which only symptomatic
treatments are available. Repurposing drugs that target α-synuclein aggregation …
treatments are available. Repurposing drugs that target α-synuclein aggregation …
Threonine cavities are targetable motifs that control alpha-synuclein fibril growth
N Nathan Kochen, V Vasandani… - ACS chemical …, 2022 - ACS Publications
Recent high-resolution structures of alpha-synuclein (aSyn) fibrils offer promise for rational
approaches to drug discovery for Parkinson's disease and Lewy body dementia. Harnessing …
approaches to drug discovery for Parkinson's disease and Lewy body dementia. Harnessing …
Post-translational modification sites are present in hydrophilic cavities of alpha-synuclein, tau, FUS, and TDP-43 fibrils: A molecular dynamics study
NN Kochen, D Seaney, V Vasandani, MG Murray… - Biophysical …, 2024 - cell.com
The molecular determinants of protein aggregation into amyloid fibrils are currently poorly
understood and are required to develop targeted therapies capable of modulating this …
understood and are required to develop targeted therapies capable of modulating this …
The Interaction of Curcumin and Rosmarinic Acid with Non‐Amyloid‐Component Domain of Alpha‐Synuclein: A Molecular Dynamics Study
M Rezaei Kamelabad, J Jahanbin Sardroodi… - …, 2020 - Wiley Online Library
One notable phenomenon in the Parkinson's disease (PD) treatment is the identification of
inhibitors of the self‐assembly of Alpha‐Synuclein (AS) protein. Here, the interactions of two …
inhibitors of the self‐assembly of Alpha‐Synuclein (AS) protein. Here, the interactions of two …
Structural influence and interactive binding behavior of dopamine and norepinephrine on the greek-key-like core of α-Synuclein protofibril revealed by molecular …
The pathogenesis of Parkinson's disease (PD) is closely associated with the aggregation of
α-synuclein (αS) protein. Finding the effective inhibitors of αS aggregation has been …
α-synuclein (αS) protein. Finding the effective inhibitors of αS aggregation has been …